A reoperative SAVR to replace a degenerated biologic prosthetic valve carries a high risk in elderly patients with complicating comorbidities [Gotzmann 2010; Eggebrecht 2011; Neragi-Miandoab 2013b] . TAVI, through the valve-in-valve technique, presents a promising option in the management of patients with degenerated bioprosthetic valves [Eggebrecht 2011] . Although the hemodynamic improvement following transcatheter valve-in-valve procedures is acceptable [Eggebrecht 2011; Linke 2012] , this approach has some limitations. Hemodynamics of valve-in-valve intervention using a small bioprosthetic valve (19 and 21 mm) are less favorable with the transcatheter approach compared to the surgical approach [Azadani 2010] . A native stenosed aortic valve preserves some flexibility and allows expansion of the prosthesis; however, a calcified and rigid bioprosthesis may prevent full expansion of a new and oversized prosthetic valve within the old valve, disrupting leaflet function. Therefore, an oversized transcatheter valve is not recommended for the valve-in-valve approach due to the risk of central aortic insufficiency. Aortic root anatomy, coronary ostial position, and the specifics of the bioprosthetic valve type (particularly valve height) need to be individualized to each specific case [Gurvitch 2011] .
Considering the high cost of TAVI, some authors have raised the issue of the cost-effectiveness of TAVI and the patient's quality of life after this procedure [Hartman 2008; . In the targeted population of patients with multiple coexisting conditions, limited life expectancy, and disproportionate health care expenditures [Hartman 2008 ], a careful consideration of cost-benefit analysis of TAVI is suggested. This is especially crucial in an era with an increasingly aging population and ongoing health care reforms aimed at reducing expenses in North America and Europe. Further, the marketing approval for a high-risk device should be based on specific indications . However, those indications should be based on clinical studies and guided by physicians rather than authorities that grant approval for the devices. and the need for refinement and improvement of its technology are valid, interpretation of inconsistencies in clinical trials and shortcomings are often misguided and used to inappropriately reject the potential of new technology. The inconsistencies in clinical trials need to be discussed independently of the product under investigation. The introduction of laparoscopic cholecystectomy and an endovascular approach for the management of abdominal and thoracic aortic pathology was subject to the same concerns and rejections decades ago.
While bearing in mind the basic medical principle of respecting human life-primum non nocere-innovation remains one of the most crucial aspects driving our field. New technologies must be granted a fair chance of introduction to all markets as soon as safety concerns are addressed. Currently, a number of next-generation transcatheter aortic valves are under pivotal clinical trials in Europe and the United States. Each of the valves under development offers a potentially significant innovation that could simplify TAVI and improve clinical outcomes. Future areas of innovation should include technologies specifically designed for treatment of bicuspid aortic valve stenosis, transcatheter valve implantation for treatment of aortic regurgitation, and valve-in-valve techniques. Next-generation transcatheter aortic valves will have to address remaining TAVI-specific drawbacks, such as periprosthetic aortic regurgitation and conduction disturbance, to further reduce the rate of complications.
